Alzheimer's Disease MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852
Conditions
Interventions
Product Name: ACI-24
Product Code: ACI-24
Pharmaceutical Form: Suspension for injection
Other descriptive name: Pal1-15 acetate salt
Concentration unit: µg/ml microgram(s)/millilitre
Concentration typ
Sponsors
AC Immune SA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Probable AD according to NINCDS-ADRDA criteria 2. Florbetaben-PET scan at screening consistent with the presence of amyloid pathology 3. Mini-Mental Status Examination (MMSE) 18 – 28 points* 4. Age over 40 and less than 90 years** 5. Patients receiving a stable dose of an acetylcholinesterase inhibitor for at least 4 months prior to baseline 6. Patients cared for by a reliable spouse or caregiver to assure compliance, assist with clinical assessments and report safety issues 7. Women must be post-menopausal for at least one year, surgically sterilized or using reliable contraceptive measures 8. Patient who in the opinion of the investigator are able to understand and provide written informed consent 9. Patients and caregivers must be fluent in one of the languages of the study and able to comply with all study procedures 10. The patient is lucid and clear and oriented x4 and is able to provide their written informed consent (applicable in Sweden only). * For cohort 3 booster injection, the previous lower limit of 18 points for the MMSE will not be required but in all cases patients must be oriented in time, place, person and current activities and able to give informed consent in the opinion of the investigator in order to take part. ** For cohort 3 booster injection, no upper age limit applies. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 58 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 140
Exclusion criteria
Exclusion criteria: 1. Patients whose MRI scan within the last 6 months shows alternative pathology including severe vascular encephalopathy and/or more than 5 micro-haemorrhages. 2. Patients with other medical conditions which may influence cognitive performance e.g. Parkinson’s disease 3. Patients with any unstable medical condition (e.g. epilepsy, uncontrolled hypertension) which would hamper safety assessments 4. Patients receiving memantine within 3 months prior to baseline (for cohort 3 booster injection, memantine is allowed) 5. Patients receiving any anticoagulant drugs 6. Patients with a history of hemorrhagic stroke 7. Patients with a history of non-hemorrhagic stroke or myocardial infarction within the last year 8. Patients with a history of major psychiatric disorder within the past 2 years 9. Patients with a history of inflammatory neurology disorders including meningoencephalitis 10. Clinically significant abnormalities of clinical haematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal of SGOT, SGPT, or creatinine 11. Patients with a history of autoimmune disease 12. Patients with a history of cancer other than skin cancer within the past 5 years 13. Patients who have received any vaccine within the past 2 months before baseline 14. Patients who have previously received AD immune therapeutic agents or vaccines except ACI-24 15. Patients anticipated to receive any vaccination other than influenza vaccine during the study 16. Patients unable to undergo MRI examination for any reason, including metal implants and claustrophobia 17. Patients with a positive HIV test at screening 18. Patients with positive syphilis serology 19. Women who are pregnant or planning to be pregnant, or who are lactating
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): - Safety and tolerability assessments: Adverse events; global assessment of tolerability; physical-, neurological- and psychiatric examination; vital signs; MRI imaging; electrocardiogram; routine hematology and biochemistry evaluation in blood- and urine; inflammatory markers in blood and cerebrospinal fluid - Biological assessments: Immune response titer (serum anti-Aß1-42 IgG titer) - Efficacy assessments: Change from baseline over 1 year of total Cognitive score (Neuropsychological Test Battery) (for Step 2 only);Timepoint(s) of evaluation of this end point: - Safety and Tolerability: all time points - Biological assessments: at multiple visits - Efficacy assessments: NTB change from baseline at different visits;Main Objective: The overall study objective is to assess the safety, immunogenicity and efficacy of repeated doses of ACI-24 at 4 different dose levels administered to patients with mild to moderate Alzheimer’s disease (AD) patients.;Secondary Objective: The secondary objectives of this trial are to explore: - the efficacy of ACI-24 in reducing Aß level in the brain of patients with mild to moderate Alzheimer’s disease - the effect of ACI-24 on whole brain and hippocampal volume (for Step 2 only) - the effect of ACI-24 on T cell activation - the effects of ACI-24 on putative biomarkers of the progression of Alzheimer’s disease like total tau and phosphorylated tau protein (phosphotau) and Aß levels (Aß1-42 and Aß1-40) in blood and CSF - the efficacy of ACI-24 on clinical/cognitive endpoints in patients with mild to moderate Alzheimer’s disease - the induction of immune response in serum and/or CSF including, but not limited to, anti-Aß1-42 IgM titer in blood - the induction of inflammatory cytokines in blood | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): - Biological assessments: Brain Aß assessed by PET amyloid imaging, whole brain and hippocampal volume assessed by MRI (for Step 2 only), T-cell activation assessed by ELISPOT analysis, Inflammatory cytokines titer in blood, Biomarkers in blood and CSF (e.g. total tau and phosphotau and Aß levels (Aß1-42 and Aß1-40)), Immune response in blood/CSF (e.g. anti-Aß1-42 IgM titer in blood and anti-Aß1-42 IgG titer in blood/CSF), TLR4 expression, TLRs and NLRs expression - Efficacy assessments: Global function [change from baseline in CDR (Clinical Dementia Rating Scale) sum of boxes], Activities of Daily Living (ADL) [change from baseline in Disability Assessment in Dementia (DAD)], other cognitive tests [change from baseline in ADAS-cog, MMSE, total NTB (including individual components, for Step 1 only)]; Behavior (change from baseline in NPI);Timepoint(s) of evaluation of this end point: - Biological assessments: at multiple visits - Efficacy assessments: at multiple visits | — |
Countries
Denmark, Finland, Sweden
Contacts
Public ContactClinical Trial Information
AC Immune SA
Outcome results
None listed